Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aldioxa→

Aldioxa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
5579-81-7
Molecular formula
C4H9AlN4O5
Molecular weight
220.12 g/mol
Drug class
Gastroprotective aluminium complexmucosal protective and anti-ulcer agent
Mechanism of action
A complex of dihydroxyaluminium and allantoin. Aluminium hydroxide-related components provide local mucosal coating and protection, while the allantoin moiety has reported anti-inflammatory and tissue-protective effects. The precise clinical mechanism is not fully established.
Indications / reported uses
  • Historically and in some countries used for symptomatic treatment of gastritis, gastric irritation and peptic ulcer-related symptoms; current indications and availability are product- and jurisdiction-specific.

Sources: https://pubmed.ncbi.nlm.nih.gov/26620883/ · https://www.nature.com/articles/srep17519 · https://pubchem.ncbi.nlm.nih.gov/#query=aldioxa · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aldioxa Environmental Risk Assessment (ERA) (the Aldioxa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.